Aspira Women's Health INC 8-K filings
Aspira Womens Health Inc. received a notice from Nasdaq regarding a violation of Listing Rule 5635(c) due to a private placement below market value, but regained compliance by amending the warrants to prohibit exercise until shareholder approval.
Aspira Women's Health reports the resignation of its President, Dr. Sandra Milligan, and the appointment of Ellen Beausang to the Board of Directors.
Aspira Women's Health has appointed Michael Buhle as CEO and James Crawford as VP of Finance, effective January 28, 2025.
Aspira Women's Health Inc. announces an upcoming investor presentation scheduled for January 13, 2025.
Aspira Womens Health Inc. has accepted the resignation of its Interim Chief Financial Officer, John Kallassy, effective January 10, 2025, and reinstated the CEO's full salary.
Aspira Women's Health Inc. received notice from Nasdaq that it failed to meet the minimum market value requirement for continued listing and faces potential delisting.
Aspira Women's Health CEO Nicole Sandford has stepped down effective immediately due to a family health matter, with President Dr. Sandra Milligan appointed as interim CEO.
Aspira Women's Health announced its third quarter 2024 financial results, showcasing growth in OvaWatch product volume and a significant ARPA-H contract award.
Aspira Women's Health Inc. presented an overview of its product pipeline status on October 29, 2024.
Aspira Women's Health has been awarded $10 million by the Advanced Research Projects Agency for Health (ARPA-H) to develop a novel blood test for endometriosis detection.
Aspira Womens Health has been awarded $10 million by ARPA-H to advance the development of a non-invasive blood test for endometriosis detection.
Aspira Womens Health Inc. received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing its listing at risk.
Aspira Women's Health Inc. released an investor presentation on September 9, 2024, as disclosed in a Form 8-K filing.
Aspira Women's Health announced its second quarter 2024 financial results, highlighting a decrease in cash utilization and growth in OvaWatch product volume, while also reporting a slight decrease in product revenue compared to the same period last year.
Aspira Women's Health has entered into an agreement to sell up to $4.45 million of its common stock through an at-the-market offering.
Aspira Women's Health has entered into a warrant inducement agreement, generating approximately $2.14 million in gross proceeds by encouraging the exercise of existing warrants at a reduced price.
Aspira Women's Health has appointed John Ragard, a seasoned investment professional, to its Board of Directors, effective July 25, 2024.
Aspira Women's Health has been notified by Nasdaq that it is not in compliance with the minimum market value of listed securities requirement and has until December 30, 2024 to regain compliance.
Aspira Women's Health has announced a private placement to raise approximately $1.935 million through the sale of common stock and warrants to existing shareholders and company insiders.
Aspira Women's Health has terminated its Chief Financial Officer, Dr. Torsten Hombeck, for cause due to a personal civil matter, with CEO Nicole Sandford assuming the role on an interim basis.
Aspira Women's Health announced significant growth in OvaSuite product volume, expanded insurance coverage, and anticipates lower cash usage for 2024.
Aspira Women's Health Inc. has amended its employment agreement with CFO Torsten Hombeck, appointing him as Corporate Secretary and increasing his base salary to $375,000.
Aspira Women's Health reported a 114% increase in OvaWatch volume and a 22% decrease in cash utilization in the first quarter of 2024, alongside the launch of a new longitudinal monitoring feature.
Aspira Women's Health successfully held its 2024 annual meeting, electing all director nominees and approving key proposals including an amendment to the stock incentive plan.
Aspira Women's Health has filed a prospectus supplement to sell up to $3.2 million of common stock under an existing agreement with Lincoln Park Capital.
Aspira Womens Health Inc. reports the resignation of Minh Merchant, the General Counsel, Chief Compliance Officer, and Corporate Secretary, effective May 6, 2024.
Aspira Women's Health announced a 15% increase in OvaSuite revenue for 2023 and a significant reduction in cash utilization.
Aspira Women's Health has amended its employment agreement with CFO Torsten Hombeck, introducing performance-based bonuses tied to successful financing transactions.
Aspira Women's Health has appointed Sandra Milligan, M.D., J.D., as President, effective April 1, 2024, to enhance its senior management team.
Aspira Women's Health Inc. secures approximately $5.5 million through a registered direct offering and concurrent private placement, issuing common stock and pre-funded warrants.